Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weber, D.
Right arrow Articles by Alexanian, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weber, D.
Right arrow Articles by Alexanian, R.
Journal of Clinical Oncology, Vol 21, Issue 1 (January), 2003: 16-19
© 2003 American Society for Clinical Oncology

Thalidomide Alone or With Dexamethasone for Previously Untreated Multiple Myeloma

Donna Weber, Kim Rankin, Maria Gavino, Kay Delasalle, Raymond Alexanian

From the The University of Texas MD Anderson Cancer Center, Houston, TX.

Address reprint requests to Donna Weber, MD, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 429, Houston, TX 77030, email: dmweber{at}mdanderson.org.

Purpose: To evaluate the activity of thalidomide in patients with asymptomatic multiple myeloma and of thalidomide-dexamethasone in patients with previously untreated symptomatic myeloma.

Patients and Methods: Twenty-eight patients with previously untreated asymptomatic myeloma were treated with thalidomide 100 to 200 mg orally (PO) at bedtime (qhs) with serial increments of 50 to 100 mg at weekly intervals, as tolerated to a maximum of 600 mg PO qhs. Forty consecutive previously untreated patients with symptomatic myeloma were also treated as above (maximum dose 400 mg) and received dexamethasone 20 mg/m2 for 4 days beginning on days 1, 9, and 17; the second and third cycles of repeated dexamethasone were begun on day 30. Both groups of patients were treated for at least 3 months.

Results: The response rate was 36% for patients treated with thalidomide alone and 72% for patients treated with thalidomide-dexamethasone, the latter including complete remission in 16% of patients. The median time to remission was 4.2 months with thalidomide alone and 0.7 months with thalidomide-dexamethasone. Grade 3 toxicity included infections (nine patients) and thrombotic/embolic events (seven patients). Five deaths have occurred as a result of multiple myeloma (two patients), infection (one patient), unknown cause (one patient), and a possible thromboembolic event (one patient).

Conclusion: Thalidomide alone was effective in patients with newly diagnosed myeloma. The combination with dexamethasone induced a high frequency of response, rapid onset of remission, and low incidence of serious irreversible toxicity. These observations support further studies of this promising combination for patients with newly diagnosed multiple myeloma.

Supported by the myeloma research funds established by Hill and Knowlton (in honor of William Max Watson) and Kay Laro.

Thalidomide provided by Celgene Corporation, Warren, NJ.




This article has been cited by other articles:


Home page
 Ann OncolHome page
C. Lafaras, E. Mandala, E. Verrou, D. Platogiannis, N. Barbetakis, T. Bischiniotis, and K. Zervas
Nonthromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: A pilot study
Ann. Onc., May 13, 2008; (2008) mdn287v1.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. V. Rajkumar, L. Rosinol, M. Hussein, J. Catalano, W. Jedrzejczak, L. Lucy, M. Olesnyckyj, Z. Yu, R. Knight, J. B. Zeldis, et al.
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma
J. Clin. Oncol., May 1, 2008; 26(13): 2171 - 2177.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Palumbo, T. Facon, P. Sonneveld, J. Blade, M. Offidani, F. Gay, P. Moreau, A. Waage, A. Spencer, H. Ludwig, et al.
Thalidomide for treatment of multiple myeloma: 10 years later
Blood, April 15, 2008; 111(8): 3968 - 3977.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
E. N. Brown and J. D. Herrington
Review of the Relationship Between Venous Thromboembolism, Malignancy and Its Treatment
Journal of Pharmacy Practice, April 1, 2008; 21(2): 126 - 137.
[Abstract] [PDF]

Home page
 JCOHome page
A. A. Chanan-Khan and B. D. Cheson
Lenalidomide for the Treatment of B-Cell Malignancies
J. Clin. Oncol., March 20, 2008; 26(9): 1544 - 1552.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Abdelkefi, S. Ladeb, L. Torjman, T. B. Othman, A. Lakhal, N. B. Romdhane, H. E. Omri, M. Elloumi, H. Belaaj, R. Jeddi, et al.
Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial
Blood, February 15, 2008; 111(4): 1805 - 1810.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. Niesvizky, D. S. Jayabalan, P. J. Christos, J. R. Furst, T. Naib, S. Ely, J. Jalbrzikowski, R. N. Pearse, F. Zafar, K. Pekle, et al.
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.
Blood, February 1, 2008; 111(3): 1101 - 1109.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. Bensinger
Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Drugs
J. Clin. Oncol., January 20, 2008; 26(3): 480 - 492.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
H. M. Lokhorst, I. Schmidt-Wolf, P. Sonneveld, B. van der Holt, H. Martin, R. Barge, U. Bertsch, J. Schlenzka, G. M.J. Bos, S. Croockewit, et al.
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma
Haematologica, January 1, 2008; 93(1): 124 - 127.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
A. A. Khorana, H. A. Liebman, R. H. White, T. Wun, and G. H. Lyman
The Risk of Venous Thromboembolism in Patients with Cancer
ASCO Educational Book, January 1, 2008; 2008(1): 240 - 248.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. M. Weber, C. Chen, R. Niesvizky, M. Wang, A. Belch, E. A. Stadtmauer, D. Siegel, I. Borrello, S. V. Rajkumar, A. A. Chanan-Khan, et al.
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
N. Engl. J. Med., November 22, 2007; 357(21): 2133 - 2142.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Gesundheit, A. Moser, R. Or, and G. Klement
Successful Antiangiogenic Therapy for Neuroblastoma With Thalidomide
J. Clin. Oncol., November 20, 2007; 25(33): 5321 - 5324.
[Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
K. V. Rao
Lenalidomide in the treatment of multiple myeloma
Am. J. Health Syst. Pharm., September 1, 2007; 64(17): 1799 - 1807.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K Zervas, D Mihou, E Katodritou, A Pouli, C. Mitsouli, A Anagnostopoulos, S Delibasi, M. Kyrtsonis, N Anagnostopoulos, E Terpos, et al.
VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek myeloma study group
Ann. Onc., August 1, 2007; 18(8): 1369 - 1375.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. Manochakian, K. C. Miller, and A. A. Chanan-Khan
Clinical Impact of Bortezomib in Frontline Regimens for Patients with Multiple Myeloma
Oncologist, August 1, 2007; 12(8): 978 - 990.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. G. Richardson, C. Mitsiades, R. Schlossman, N. Munshi, and K. Anderson
New Drugs for Myeloma
Oncologist, June 1, 2007; 12(6): 664 - 689.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J.-P. Armand, A. K. Burnett, J. Drach, J.-L. Harousseau, B. Lowenberg, and J. San Miguel
The Emerging Role of Targeted Therapy for Hematologic Malignancies: Update on Bortezomib and Tipifarnib
Oncologist, March 1, 2007; 12(3): 281 - 290.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. G. Richardson, E. Blood, C. S. Mitsiades, S. Jagannath, S. R. Zeldenrust, M. Alsina, R. L. Schlossman, S. V. Rajkumar, K. R. Desikan, T. Hideshima, et al.
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
Blood, November 15, 2006; 108(10): 3458 - 3464.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Attal, J.-L. Harousseau, S. Leyvraz, C. Doyen, C. Hulin, L. Benboubker, I. Y. Agha, J.-H. Bourhis, L. Garderet, B. Pegourie, et al.
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma
Blood, November 15, 2006; 108(10): 3289 - 3294.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
H. P. Sviggum, M. D. P. Davis, S. V. Rajkumar, and A. Dispenzieri
Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma.
Arch Dermatol, October 1, 2006; 142(10): 1298 - 1302.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Offidani, L. Corvatta, M.-N. Piersantelli, G. Visani, F. Alesiani, M. Brunori, P. Galieni, M. Catarini, M. Burattini, R. Centurioni, et al.
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma
Blood, October 1, 2006; 108(7): 2159 - 2164.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. A. Zonder, B. Barlogie, B. G. M. Durie, J. McCoy, J. Crowley, M. A. Hussein, S. V. Rajkumar, and M. A. Gertz
Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis.
Blood, July 1, 2006; 108(1): 403 - 404.
[Full Text] [PDF]

Home page
 BloodHome page
B. Barlogie, G. Tricot, E. Rasmussen, E. Anaissie, F. van Rhee, M. Zangari, A. Fassas, K. Hollmig, M. Pineda-Roman, J. Shaughnessy, et al.
Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies
Blood, April 1, 2006; 107(7): 2633 - 2638.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
B. Barlogie, G. Tricot, E. Anaissie, J. Shaughnessy, E. Rasmussen, F. van Rhee, A. Fassas, M. Zangari, K. Hollmig, M. Pineda-Roman, et al.
Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
N. Engl. J. Med., March 9, 2006; 354(10): 1021 - 1030.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Barlogie, R. A. Kyle, K. C. Anderson, P. R. Greipp, H. M. Lazarus, D. D. Hurd, J. McCoy, S. R. Dakhil, K. S. Lanier, R. A. Chapman, et al.
Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321
J. Clin. Oncol., February 20, 2006; 24(6): 929 - 936.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. V. Rajkumar, E. Blood, D. Vesole, R. Fonseca, and P. R. Greipp
Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group
J. Clin. Oncol., January 20, 2006; 24(3): 431 - 436.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Richardson and K. Anderson
Thalidomide and Dexamethasone: A New Standard of Care for Initial Therapy in Multiple Myeloma
J. Clin. Oncol., January 20, 2006; 24(3): 334 - 336.
[Full Text] [PDF]

Home page
 ASH Education BookHome page
R. Z. Orlowski
Initial Therapy of Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplantation
Hematology, January 1, 2006; 2006(1): 338 - 347.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
J. A. Zonder
Thrombotic Complications of Myeloma Therapy
Hematology, January 1, 2006; 2006(1): 348 - 355.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Moreau, C. Hullin, F. Garban, I. Yakoub-Agha, L. Benboubker, M. Attal, G. Marit, J.-G. Fuzibet, C. Doyen, L. Voillat, et al.
Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol
Blood, January 1, 2006; 107(1): 397 - 403.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J.-P. Fermand, S. Katsahian, M. Divine, V. Leblond, F. Dreyfus, M. Macro, B. Arnulf, B. Royer, X. Mariette, E. Pertuiset, et al.
High-Dose Therapy and Autologous Blood Stem-Cell Transplantation Compared With Conventional Treatment in Myeloma Patients Aged 55 to 65 Years: Long-Term Results of a Randomized Control Trial From the Group Myelome-Autogreffe
J. Clin. Oncol., December 20, 2005; 23(36): 9227 - 9233.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. D. Schwartz, M. Sung, M. Schwartz, D. Lehrer, J. Mandeli, L. Liebes, A. Goldenberg, and M. Volm
Thalidomide in Advanced Hepatocellular Carcinoma with Optional Low-Dose Interferon-{alpha}2a upon Progression
Oncologist, October 1, 2005; 10(9): 718 - 727.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
G. Saunders
Overview of drug therapy for multiple myeloma
Journal of Oncology Pharmacy Practice, September 1, 2005; 11(3): 83 - 100.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
H M. Prince, L. Mileshkin, A. Roberts, V. Ganju, C. Underhill, J. Catalano, R. Bell, J. F. Seymour, D. Westerman, P. J. Simmons, et al.
A Multicenter Phase II Trial of Thalidomide and Celecoxib for Patients with Relapsed and Refractory Multiple Myeloma
Clin. Cancer Res., August 1, 2005; 11(15): 5504 - 5514.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Ferrone and G. Sconocchia
A clinically relevant mouse model of human multiple myeloma?
Blood, July 15, 2005; 106(2): 388 - 389.
[Full Text] [PDF]

Home page
 BloodHome page
M. Cavo, E. Zamagni, P. Tosi, P. Tacchetti, C. Cellini, D. Cangini, A. de Vivo, N. Testoni, C. Nicci, C. Terragna, et al.
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma
Blood, July 1, 2005; 106(1): 35 - 39.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. G. Richardson, P. Sonneveld, M. W. Schuster, D. Irwin, E. A. Stadtmauer, T. Facon, J.-L. Harousseau, D. Ben-Yehuda, S. Lonial, H. Goldschmidt, et al.
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
N. Engl. J. Med., June 16, 2005; 352(24): 2487 - 2498.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
A. Dispenzieri
Bortezomib for Myeloma -- Much Ado about Something
N. Engl. J. Med., June 16, 2005; 352(24): 2546 - 2548.
[Full Text] [PDF]

Home page
 BloodHome page
G. Palladini, V. Perfetti, S. Perlini, L. Obici, F. Lavatelli, R. Caccialanza, R. Invernizzi, B. Comotti, and G. Merlini
The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL)
Blood, April 1, 2005; 105(7): 2949 - 2951.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Gasparini, R. Longo, M. Fanelli, and B. A. Teicher
Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions
J. Clin. Oncol., February 20, 2005; 23(6): 1295 - 1311.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. G. Richardson, A. Kassarjian, and W. Jing
Case 38-2004 - A 40-Year-Old Man with a Large Tumor of the Skull
N. Engl. J. Med., December 16, 2004; 351(25): 2637 - 2645.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. K. Stewart, C. I. Chen, K. Howson-Jan, D. White, J. Roy, M. J. Kovacs, C. Shustik, A. Sadura, L. Shepherd, K. Ding, et al.
Results of a Multicenter Randomized Phase II Trial of Thalidomide and Prednisone Maintenance Therapy for Multiple Myeloma after Autologous Stem Cell Transplant
Clin. Cancer Res., December 15, 2004; 10(24): 8170 - 8176.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Chintagumpala, S. M. Blaney, L. R. Bomgaars, A. Aleksic, J. F. Kuttesch, R. A. Klenke, and S. L. Berg
Phase I and Pharmacokinetic Study of Thalidomide With Carboplatin in Children With Cancer
J. Clin. Oncol., November 1, 2004; 22(21): 4394 - 4400.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. A. Kyle and S. V. Rajkumar
Multiple Myeloma
N. Engl. J. Med., October 28, 2004; 351(18): 1860 - 1873.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Chung, J. Lu, B. D. Palmer, P. Kestell, P. Browett, B. C. Baguley, M. Tingle, and L.-M. Ching
Thalidomide Pharmacokinetics and Metabolite Formation in Mice, Rabbits, and Multiple Myeloma Patients
Clin. Cancer Res., September 1, 2004; 10(17): 5949 - 5956.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Richardson and K. Anderson
Immunomodulatory Analogs of Thalidomide: An Emerging New Therapy in Myeloma
J. Clin. Oncol., August 15, 2004; 22(16): 3212 - 3214.
[Full Text] [PDF]

Home page
 Ann OncolHome page
V. Eleutherakis-Papaiakovou, A. Bamias, and M. A. Dimopoulos
Thalidomide in cancer medicine
Ann. Onc., August 1, 2004; 15(8): 1151 - 1160.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Hideshima, P. L. Bergsagel, W. M. Kuehl, and K. C. Anderson
Advances in biology of multiple myeloma: clinical applications
Blood, August 1, 2004; 104(3): 607 - 618.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. L. Dahut, J. L. Gulley, P. M. Arlen, Y. Liu, K. M. Fedenko, S. M. Steinberg, J. J. Wright, H. Parnes, C. C. Chen, E. Jones, et al.
Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer
J. Clin. Oncol., July 1, 2004; 22(13): 2532 - 2539.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Kumar, T. E. Witzig, and S. V. Rajkumar
Thalidomide: Current Role in the Treatment of Non-Plasma Cell Malignancies
J. Clin. Oncol., June 15, 2004; 22(12): 2477 - 2488.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. F. Bross, R. Kane, A. T. Farrell, S. Abraham, K. Benson, M. E. Brower, S. Bradley, J. V. Gobburu, A. Goheer, S.-L. Lee, et al.
Approval Summary for Bortezomib for Injection in the Treatment of Multiple Myeloma
Clin. Cancer Res., June 15, 2004; 10(12): 3954 - 3964.
[Full Text] [PDF]

Home page
 Ann OncolHome page
K. Zervas, M. A. Dimopoulos, E. Hatzicharissi, A. Anagnostopoulos, M. Papaioannou, Ch. Mitsouli, P. Panagiotidis, J. Korantzis, M. Tzilianos, and A. Maniatis
Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study
Ann. Onc., January 1, 2004; 15(1): 134 - 138.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
J.-L. Harousseau, J. Shaughnessy Jr., and P. Richardson
Multiple Myeloma
Hematology, January 1, 2004; 2004(1): 237 - 256.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. Barlogie, J. Shaughnessy, G. Tricot, J. Jacobson, M. Zangari, E. Anaissie, R. Walker, and J. Crowley
Treatment of multiple myeloma
Blood, January 1, 2004; 103(1): 20 - 32.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Dimopoulos, A. Anagnostopoulos, and D. Weber
Treatment of Plasma Cell Dyscrasias With Thalidomide and Its Derivatives
J. Clin. Oncol., December 1, 2003; 21(23): 4444 - 4454.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
E. K. Rowinsky
Crossing the Cancer Cell Membrane to Improve Clinical Outcomes
Oncologist, December 1, 2003; 8(90003): 1 - 4.
[Full Text] [PDF]
<